Study to Evaluate Safety and Effectiveness of Spinal Sealant
Primary Purpose
Spinal Procedure Requiring Dura Incision
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Spinal Sealant System
Standard of care
Sponsored by
About this trial
This is an interventional treatment trial for Spinal Procedure Requiring Dura Incision focused on measuring Spinal procedure, Dura incision
Eligibility Criteria
Inclusion Criteria:
- Patients who are scheduled for an elective spinal procedure that requires a dural incision will be considered for study participation.
- Patient requires a procedure that involving surgical wound classification Class 1/Clean (per CDC criteria)
- Presence of a non-watertight dural closure, either spontaneously or upon Valsala maneuver at 20-25 cm H20 for 5-10 seconds.
Exclusion Criteria:
- Active spinal and/or systemic infection
- Patient requires additional spinal surgery within the study time period
- Patient has had a previous spinal surgery involving dural exposure and/or entry at the same level(s) as the study procedure
- Patient has a pre-existing external lumbar CSF drain or internal CSF shunt
- Patient is participating in a clinical trial of another investigational device or drug
- Patient with creatinine > 2.0 mg/dL
- Patient with total bilirubin > 2.5 mg/dL
- Pregnant or breast-feeding females or females who wish to become pregnant during the length of study participation
- Patient has been treated with chronic steroid therapy (>4 weeks) unless discontinued more than 6 weeks prior to surgery
- Patient has documented history or significant coagulopathy with a PTT >35 sec, PT/INR >1.2, receiving asprin, or NSAIDS at the time of surgery
- Patient receiving warfarin or heparin at the time of surgery
- Patient has a diagnosed and documented compromised immune system and/or autoimmune disease
- Patient has has chemotherapy treatment within 6 months prior to, or planned during the study
- Patient has had prior radiation treatment to the surgical site or has planned radiation therapy within 30 days post procedure
- Patient has known malignancy or other condition with prognosis shorter than 6 months
- Patients with documented history of uncontrolled diabetes
- Patient requires use of synthetic or non-autologous duraplasty material
- Patient has a gap greater than 2mm remaining after primary dural closure
- Patient has undergone laminoplasty decompression
- Patient has undergone a syringomyelia procedure where the shunt is not placed in the subarachnoid position
- Patient has undergone a Chiari Malformation procedure that does not entail a dural incision at or below the C1 level
- The investigator determines that participation in the study may jeopardize the safety or welfare of the patient
- The investigator determines that the patient should not be included in the study for reason(s) not already specified
Sites / Locations
- Confluent Surgical, Inc.
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Spinal Sealant
Standard of care
Outcomes
Primary Outcome Measures
Watertight Dural Closure
Number of subjects displaying a watertight dural closure after assigned treatment intra-operatively.
Secondary Outcome Measures
Full Information
NCT ID
NCT00594035
First Posted
January 2, 2008
Last Updated
August 7, 2017
Sponsor
Integra LifeSciences Corporation
1. Study Identification
Unique Protocol Identification Number
NCT00594035
Brief Title
Study to Evaluate Safety and Effectiveness of Spinal Sealant
Official Title
A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
February 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Integra LifeSciences Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the safety and efficacy of the Spinal Sealant as an adjunct to sutured dural repair compared with standard of care methods (control) to obtain watertight dural closure in patients undergoing spinal surgery.
Detailed Description
Neurosurgical procedures in the spine often involve incision of the dura mater to access the spinal cord. If the dural incision is not properly repaired and watertight closure is not achieved cerebrospinal fluid (CSF) can escape presenting a risk for significant morbidity. The most frequent complication of CSF leak is recurring headache complicated with symptoms of nausea and vomiting. Furthermore fluid collection under skin prevents proper wound healing and may lead to wound breakdown and infection of the incision or both. Persistent CSF leak has also been associated with the development of cerebellar hemorrhage and subdural hematoma. Primary repair and watertight closure are paramount to minimizing risk and sequelae associated with CSF leak.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Procedure Requiring Dura Incision
Keywords
Spinal procedure, Dura incision
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
158 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Spinal Sealant
Arm Title
2
Arm Type
Active Comparator
Arm Description
Standard of care
Intervention Type
Device
Intervention Name(s)
Spinal Sealant System
Intervention Type
Device
Intervention Name(s)
Standard of care
Other Intervention Name(s)
(i.e. devices intended to provide a watertight closure)
Intervention Description
Standard of care: devices intended to provide a watertight closure
Primary Outcome Measure Information:
Title
Watertight Dural Closure
Description
Number of subjects displaying a watertight dural closure after assigned treatment intra-operatively.
Time Frame
Intra-Operative
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who are scheduled for an elective spinal procedure that requires a dural incision will be considered for study participation.
Patient requires a procedure that involving surgical wound classification Class 1/Clean (per CDC criteria)
Presence of a non-watertight dural closure, either spontaneously or upon Valsala maneuver at 20-25 cm H20 for 5-10 seconds.
Exclusion Criteria:
Active spinal and/or systemic infection
Patient requires additional spinal surgery within the study time period
Patient has had a previous spinal surgery involving dural exposure and/or entry at the same level(s) as the study procedure
Patient has a pre-existing external lumbar CSF drain or internal CSF shunt
Patient is participating in a clinical trial of another investigational device or drug
Patient with creatinine > 2.0 mg/dL
Patient with total bilirubin > 2.5 mg/dL
Pregnant or breast-feeding females or females who wish to become pregnant during the length of study participation
Patient has been treated with chronic steroid therapy (>4 weeks) unless discontinued more than 6 weeks prior to surgery
Patient has documented history or significant coagulopathy with a PTT >35 sec, PT/INR >1.2, receiving asprin, or NSAIDS at the time of surgery
Patient receiving warfarin or heparin at the time of surgery
Patient has a diagnosed and documented compromised immune system and/or autoimmune disease
Patient has has chemotherapy treatment within 6 months prior to, or planned during the study
Patient has had prior radiation treatment to the surgical site or has planned radiation therapy within 30 days post procedure
Patient has known malignancy or other condition with prognosis shorter than 6 months
Patients with documented history of uncontrolled diabetes
Patient requires use of synthetic or non-autologous duraplasty material
Patient has a gap greater than 2mm remaining after primary dural closure
Patient has undergone laminoplasty decompression
Patient has undergone a syringomyelia procedure where the shunt is not placed in the subarachnoid position
Patient has undergone a Chiari Malformation procedure that does not entail a dural incision at or below the C1 level
The investigator determines that participation in the study may jeopardize the safety or welfare of the patient
The investigator determines that the patient should not be included in the study for reason(s) not already specified
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vladimir Scerbin
Organizational Affiliation
Medtronic - MITG
Official's Role
Study Director
Facility Information:
Facility Name
Confluent Surgical, Inc.
City
Bedford
State/Province
Massachusetts
ZIP/Postal Code
01730
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study to Evaluate Safety and Effectiveness of Spinal Sealant
We'll reach out to this number within 24 hrs